Efficacy of Boceprevir, an NS3 Protease Inhibitor, in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naive Patients With Genotype 1 Hepatitis C Infection (SPRINT-1): An Open-Label, Randomised, Multicentre Phase 2 Trial

The Lancet - United Kingdom
doi 10.1016/s0140-6736(10)60934-8
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

Elsevier BV

Related search

Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial

Gastroenterology
HepatologyGastroenterology
2016English

Peginterferon Alfa-2b and Ribavirin Therapy in Kuwaiti Patients With Chronic Hepatitis C Virus Infection

Eastern Mediterranean Health Journal
Medicine
2011English

Randomized Trial of Peginterferon Alfa-2b and Ribavirin for 48 or 72 Weeks in Patients With Hepatitis C Virus Genotype 1 and Slow Virologic Response

Hepatology
MedicineHepatology
2010English

Optimum Ribavirin Exposure Overcomes Racial Disparity in Efficacy of Peginterferon and Ribavirin Treatment for Hepatitis C Genotype 1

American Journal of Gastroenterology
HepatologyGastroenterology
2012English

Renal Dysfunction With Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin Therapy

Acta Hepatologica Japonica
Hepatology
2012English

Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections

Gastroenterology
HepatologyGastroenterology
2016English

Mixed Treatment Comparisons to Compare Simeprevir With Boceprevir and Telaprevir in Combination With Peg-Interferon Alpha and Ribavirin (Pr) in Patients Infected With Genotype 1 Hepatitis C Virus (Hcv)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

PIN50 the Clinical Efficacy and Cost-Effectiveness of Boceprevir in Combination With Pegylated Interferon- Alfa and Ribavirin for the Treatment of Genotype 1 Chronic Hepatitis C Patients: A Within Trial Analysis From the Perspective of the Scottish National Health Service (NHS)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

A1-2: Cost-Effectiveness of Interleukin 28B Genotype-Guided Protease Inhibitor Therapy in Treatment-Naive Patients With Hepatitis C Virus Genotype 2 or 3

Clinical Medicine and Research
MedicineHome CareCommunity
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy